A complete cross-over design evaluating canine acceptance of Carprieve® and Rimadyl® carprofen chewable tablets in healthy dogs

Table 1 Demographic characteristics, carprofen dose administered, and group allocation of dogs in the study

Group^*	Dog ID	Sex^±	Age, years	Weight, kg	Carprofen, mg^҂	Dose, mg/kg
I	315–974	Female	1.0	10.4	25.0	2.4
I	439–468	Male	2.1	13.0	25.0	1.9
I	439–470	Male	1.2	11.6	25.0	2.2
I	440–118	Male	2.1	7.9	12.5	1.6
I	452–270	Female	1.5	8.1	12.5	1.5
I	540–556	Female	2.1	11.7	25.0	2.1
I	597–230	Male	2.0	12.7	25.0	2.0
I	597–674	Male	2.0	10.9	25.0	2.3
I	597–892	Male	1.1	11.3	25.0	2.2
I	600–010	Female	2.0	9.8	12.5	1.3
I	600–014	Female	2.0	9.4	12.5	1.3
I	600–236	Male	2.1	9.3	12.5	1.3
I	600–344	Male	2.0	9.8	12.5	1.3
I	600–816	Female	1.5	9.7	12.5	1.3
I	600–836	Male	1.0	13.3	25.0	1.9
I	600–934	Female	2.1	8.6	12.5	1.5
I	601–472	Female	2.1	8.4	12.5	1.5
I	601–663	Male	1.8	13.0	25.0	1.9
II	312–683	Male	1.0	11.4	25.0	2.2
II	312–987	Male	1.0	11.5	25.0	2.2
II	323–648	Female	2.5	9.3	12.5	1.3
II	439–977	Male	1.0	13.0	25.0	1.9
II	440–023	Female	2.0	11.9	25.0	2.1
II	440–104	Female	1.5	8.9	12.5	1.4
II	453–072	Male	1.0	13.6	25.0	1.8
II	597–303	Female	2.1	10.1	12.5	1.2
II	597–340	Female	1.6	9.4	12.5	1.3
II	597–362	Female	1.6	8.5	12.5	1.5
II	600–104	Male	2.1	10.3	25.0	2.4
II	600–324	Female	2.1	8.6	12.5	1.5
II	600–454	Male	1.0	12.7	25.0	2.0
II	600–779	Female	1.6	8.4	12.5	1.5
II	600–904	Male	2.1	9.9	12.5	1.3
II	601–341	Male	2.0	11.0	25.0	2.3
II	601–482	Female	2.0	10.7	25.0	2.3
II	601–928	Male	1.2	13.0	25.0	1.9
II	603–754	Female	2.1	10.3	25.0	2.4

^*Group I was offered Carprieve® on day 0 and Rimadyl®; Group II was offered Rimadyl® on day 0 and Carprieve® on day 7
^±All dogs were unaltered (i.e., sexually intact)
^҂25.0 mg indicates a whole tablet was offered, 12.5 mg indicates a half tablet was offered

ISSN: 1746-6148